The Role of Galectin-3 in Endocytosis of Advanced Glycation End Products and Modified Low Density Lipoproteins
- 1 February 2001
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 280 (4) , 1183-1188
- https://doi.org/10.1006/bbrc.2001.4256
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Role of galectin-3 as a receptor for advanced glycosylation end productsKidney International, 2000
- A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infectionNature, 1997
- beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.Journal of Clinical Investigation, 1993
- Angiogenic Effects of Advanced Glycation End Products of the Maillard Reaction on Cultured Human Umbilical Cord Vein Endothelial CellsBiochemical and Biophysical Research Communications, 1993
- Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.Journal of Clinical Investigation, 1993
- Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.Journal of Clinical Investigation, 1992
- High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.The Journal of Experimental Medicine, 1991
- Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue RemodelingScience, 1988
- Efficient Trace-labelling of Proteins with IodineNature, 1958